Atlas Trials

Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL)

Clinical trial NCT03207542 · WITHDRAWN

Trial details

NCT number
NCT03207542
Sponsor
M.D. Anderson Cancer Center
Status
WITHDRAWN
Phase
Phase 2
Study type
INTERVENTIONAL
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
Start date
2018-07-01
Primary completion
2020-07-01
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.